138 related articles for article (PubMed ID: 33164013)
1. Characterisation of estrogen receptor alpha (ERα) expression in breast cancer cells and effect of drug treatment using targeted nanoparticles and SERS.
Kapara A; Brunton VG; Graham D; Faulds K
Analyst; 2020 Nov; 145(22):7225-7233. PubMed ID: 33164013
[TBL] [Abstract][Full Text] [Related]
2. Detection of Estrogen Receptor Alpha and Assessment of Fulvestrant Activity in MCF-7 Tumor Spheroids Using Microfluidics and SERS.
Kapara A; Findlay Paterson KA; Brunton VG; Graham D; Zagnoni M; Faulds K
Anal Chem; 2021 Apr; 93(14):5862-5871. PubMed ID: 33797884
[TBL] [Abstract][Full Text] [Related]
3. Investigation of cellular uptake mechanism of functionalised gold nanoparticles into breast cancer using SERS.
Kapara A; Brunton V; Graham D; Faulds K
Chem Sci; 2020 May; 11(22):5819-5829. PubMed ID: 34094083
[TBL] [Abstract][Full Text] [Related]
4. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.
Karam M; Bièche I; Legay C; Vacher S; Auclair C; Ricort JM
J Cell Mol Med; 2014 Dec; 18(12):2536-52. PubMed ID: 25287328
[TBL] [Abstract][Full Text] [Related]
6. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
[TBL] [Abstract][Full Text] [Related]
7. A clinically feasible diagnostic spectro-histology built on SERS-nanotags for multiplex detection and grading of breast cancer biomarkers.
Murali VP; Karunakaran V; Murali M; Lekshmi A; Kottarathil S; Deepika S; Saritha VN; Ramya AN; Raghu KG; Sujathan K; Maiti KK
Biosens Bioelectron; 2023 May; 227():115177. PubMed ID: 36871528
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion.
JavanMoghadam S; Weihua Z; Hunt KK; Keyomarsi K
Cell Cycle; 2016 Jun; 15(12):1579-90. PubMed ID: 27049344
[TBL] [Abstract][Full Text] [Related]
9. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
Mishra AK; Abrahamsson A; Dabrosin C
Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
13. The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor.
Casa AJ; Hochbaum D; Sreekumar S; Oesterreich S; Lee AV
Mol Cell Endocrinol; 2015 Nov; 415():76-86. PubMed ID: 26272024
[TBL] [Abstract][Full Text] [Related]
14. Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader.
Zhao Y; Zhao C; Lu J; Wu J; Li C; Hu Z; Tian W; Yang L; Xiang J; Zhou H; Deng Z; Huang J; Hong K
Pharmacol Res; 2019 Aug; 146():104294. PubMed ID: 31175940
[TBL] [Abstract][Full Text] [Related]
15. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
16. Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Zhao C; Tang C; Li C; Ning W; Hu Z; Xin L; Zhou HB; Huang J
Bioorg Med Chem; 2021 Jun; 40():116185. PubMed ID: 33965842
[TBL] [Abstract][Full Text] [Related]
17. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
18. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
19. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
Wardell SE; Marks JR; McDonnell DP
Biochem Pharmacol; 2011 Jul; 82(2):122-30. PubMed ID: 21501600
[TBL] [Abstract][Full Text] [Related]
20. Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines.
Tan H; Zhong Y; Pan Z
BMC Cancer; 2009 Jan; 9():31. PubMed ID: 19171042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
